Talecris Biotherapeutics

Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema

Awards fund early career investigators' research to advance understanding and potential treatments of alpha1-antitrypsin deficiency

RESEARCH TRIANGLE PARK, North Carolina, November 15, 2010 - Talecris Biotherapeutics announced today the publication of combined data from two studies demonstrating that augmentation therapy with Alpha(1) -Proteinase Inhibitor (Human) (A1PI) significantly reduces lung tissue loss in patients with emphysema related to Alpha(1)-antitrypsin (AAT) deficiency.

MORE..

Older News

BARCELONA, Spain, September 20, 2010 - Talecris Biotherapeutics GmbH announced yesterday the recipients of the 2010 European alpha1-antitrypsin Laurell's Training Awards (eALTA).

MORE..